Target
TMB ≥10 / MSI-H / dMMR
9 abstracts
Abstract
MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers.Org: US Medical Affairs Oncology,
Abstract
NGS panels' capture of biomarkers associated with targeted therapies in clinical trials.Org: Illumina, Inc.,
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Real-world analysis of commercially insured and Medicare Advantage patients with advanced cancer and rates of molecular testing.Org: Optum Labs, Eden Prairie, MN, Illumina, Inc., San Diego State University Department of Biology, San Diego, CA,
Abstract
Postoperative prognosis in patients with NSCLC with different EGFR mutation sites.Org: 3D Medicines Co. Ltd.,
Abstract
Role of immune checkpoint inhibitors in PDL1-negative, low TMB, stable MSI metastatic solid tumours: Single centre study.Org: HCG Cancer Centre Mumbai, Bangalore Institute of Oncology, All India Institute of Medical Sciences (AIIMS), Rishikesh, India, Vydehi Institute of Medical Sciences & Research Centre,
Abstract
Assessment of genomic profiling in patients with colorectal cancer treated in community oncology practices.Org: Compass Oncology, Ontada,
Abstract
Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational burden (TMB) in a community-based cancer center patient population in rural central Nebraska.Org: Morrison Cancer Center Mary Lanning Healthcare, Hastings, NE, Foundation Medicine, Inc., Cambridge, MA, Morrison Cancer Center, Mary Lanning Healthcare, Hastings, NE, Morrison Cancer Center, Hastings, NE, Mary Lanning Healthcare, Hastings, NE,